IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 101-125 out of 1268.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 > >>

Public Release: 10-Nov-2014
Cancer Cell
Scientists solve mystery of 'Frankenstein' DNA
Australian researchers have uncovered how the massive DNA molecules that appear in some tumours are formed like Frankenstein's monster, stitched together from other parts of the genome. This solves a decades-old mystery and explains how these tumours ensure their own survival.
National Health and Medical Research Council, Government of Victoria

Contact: Alison Heather
Garvan Institute of Medical Research

Public Release: 10-Nov-2014
Annals of Family Medicine
November/December 2014 Annals of Family Medicine tip sheet
This tip sheet features synopses of original research and commentary featured in the November/December issue of Annals of Family Medicine.

Contact: Angela Sharma
American Academy of Family Physicians

Public Release: 10-Nov-2014
Cancer Cell
Researchers find new target for kidney cancer therapy
Cincinnati Cancer Center researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease that currently has few treatment options.
National Institutes of Health, Veterans Affairs Merit Award, UC Center for Environmental Genetics Award

Contact: Katie Pence
University of Cincinnati Academic Health Center

Public Release: 10-Nov-2014
Cancer Discovery
Mayo Clinic researchers identify first steps in formation of pancreatic cancer
Researchers at Mayo Clinic's campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.
National Institutes of Health

Contact: Kevin Punsky
Mayo Clinic

Public Release: 10-Nov-2014
Molecular breakthrough could halt the spread of prostate cancer
Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer.
Prostate Cancer UK, Biotechnology and Biological Sciences Research Council

Contact: Philippa Walker
University of Bristol

Public Release: 10-Nov-2014
Physicians play a critical role in ensuring bladder cancer patients
When bladder cancer patients are well-informed by their physicians, they acknowledge that tobacco use was likely the cause of their disease.

Contact: Evelyn Martinez

Public Release: 10-Nov-2014
Journal of Clinical Oncology
Half of premature colorectal cancer deaths due to socioeconomic inequality
Half of all premature deaths from colorectal cancer -- described as deaths in people ages 25 to 64 -- in the United States are linked to ethnic, socioeconomic, and geographic inequalities, and therefore could be prevented according to a new study by American Cancer Society researchers.
American Cancer Society

Contact: David Sampson
American Cancer Society

Public Release: 10-Nov-2014
Journal of Clinical Investigation
Tumor-associated neutrophils boost anti-tumor immune responses
A new study in the Journal of Clinical Investigation suggests that tumor-associated neutraphils help bolster the immune response against lung tumors.
National Institutes of Health, Janssen Pharmaceuticals, Lung Cancer Translation Center of Excellence of the Abramson Cancer Center at the University of Pennsylvania

Contact: Corinne Williams
Journal of Clinical Investigation

Public Release: 10-Nov-2014
Cancer Cell
Classification of gene mutations in a children's cancer may point to improved treatments
Oncology researchers studying gene mutations in the children's cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations.
National Institutes of Health, US Army Peer-Reviewed Medical Research Program, National Science Foundation

Contact: Rachel Salis-Silverman
Children's Hospital of Philadelphia

Public Release: 7-Nov-2014
Nature Medicine
CNIO scientists challenge the efficacy of folfiri in a colorectal cancer subtype
They warn that an erroneous correlation between drug and 'stemlike' colon cancer subtype could lead oncologists to prescribe inadequate treatments Results are presented this week in the journal 'Nature Medicine'.

Contact: Nuria Noriega
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 7-Nov-2014
Nature Communications
No junk: Long RNA mimics DNA, restrains hormone responses
Emory researchers have obtained a detailed picture of how the Gas5 RNA interacts with steroid hormone receptors. Their findings show how the Gas5 RNA takes the place of DNA, and give hints as to how it evolved.
American Heart Association, NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Quinn Eastman
Emory Health Sciences

Public Release: 7-Nov-2014
American Society of Dermatopathology 51st Annual Meeting
Myriad myPath™ Melanoma improves diagnosis and treatment plans
Results from a prospective clinical utility study of the Myriad myPath Melanoma test presented at the 2014 American Society of Dermatopathology annual meeting found a 43 percent reduction in indeterminate diagnoses and a 49 percent change in physicians' treatment recommendations for patients.

Contact: Ronald Rogers
Myriad Genetics, Inc.

Public Release: 7-Nov-2014
A vaccine directed against tumor blood vessels suppress tumor growth and metastasis
In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumor vessels can reduce tumor burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer.

Contact: Anna-Karin Olsson
Uppsala University

Public Release: 7-Nov-2014
Journal of the American Board of Family Medicine
Nurse navigators may aid colon cancer screening follow-up
Group Health patients with a positive screening test for colon cancer (a stool test or sigmoidoscopy) tended to be more likely to get the recommended follow-up test, a diagnostic colonoscopy, if nurse navigators contacted them than if they got usual care, according to Beverly B. Green, MD, MPH, a Group Health physician and a Group Health Research Institute associate investigator.
NIH/National Cancer Institute

Contact: Joan DeClaire
Group Health Research Institute

Public Release: 7-Nov-2014
Practice makes perfect in cancer surgery
In a new, in-depth research project, Queen's professors Rob Siemens, Urology, and Christopher Booth, Cancer Care and Epidemiology, investigated what affect higher volume hospitals and surgeons had on the outcomes of patients undergoing a radical cystectomy for bladder cancer in Ontario.

Contact: Anne Craig
Queen's University

Public Release: 7-Nov-2014
Researchers take new approach to stop 'most wanted' cancer protein
Researchers have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells by turning the protein's own molecular machinations against it. They used a specially crafted compound to disrupt the protein's ability to rev up its own production and that of other proteins involved in tumor cell growth in an aggressive form of neuroblastoma. The resulting shrinkage of tumors caused little or no harm to normal cells.
National Institutes of Health, American Cancer Society, US Department of Defense, Friends for Life Neuroblastoma Foundation

Contact: Irene Sege
Dana-Farber Cancer Institute

Public Release: 6-Nov-2014
Woman's genes give clue for unique liver cancer treatment
A 47-year-old American woman with intrahepatic cholangiocarcinoma is the first person with her condition to receive a uniquely personalized treatment based on her genetic profile. 'Using the information from the genetic makeup of our patient's cancer, we were able to formulate a personalized treatment,' says Dr. Arturo Loaiza-Bonilla of the University of Pennsylvania, lead author of the case report published in ecancermedicalscience.

Contact: Katie Foxall

Public Release: 6-Nov-2014
Before there will be blood
In a paper published Nov. 20 in the journal Cell, researchers at the University of California, San Diego School of Medicine describe the surprising and crucial involvement of a pro-inflammatory signaling protein in the creation of hematopoietic stem cells (HSCs) during embryonic development, a finding that could help scientists to finally reproduce HSCs for therapeutic use.
Spanish Ministry of Science and Innovation, Fundación Séneca, Agencia Regional de Ciencia y Tecnología de la Región de Murcia, National Institutes of Health, California Institute for Regenerative Medicine

Contact: Scott LaFee
University of California - San Diego

Public Release: 6-Nov-2014
Molecular Cancer Therapeutics
Further evidence of potential for new anti-cancer drug
Manchester scientists have shown that a new drug inhibits the growth of tumors in the lab and that its effectiveness is improved by combining it with radiotherapy -- suggesting a new approach that could be used in the clinic.
Medical Research Council, AstraZeneca

Contact: Jamie Brown
University of Manchester

Public Release: 6-Nov-2014
A cause of age-related inflammation found
As animals age, their immune systems gradually deteriorate, a process called immunosenescence. It is associated with systemic inflammation and chronic inflammatory disorders, as well as with many cancers. The causes underlying this age-associated inflammation, and how it leads to diseases, are poorly understood. New work sheds light on one protein's involvement in suppressing immune responses in aging fruit flies.

Contact: Yixian Zheng
Carnegie Institution

Public Release: 6-Nov-2014
Migration negation
Researchers have now identified a cellular culprit that should help researchers better understand how metastasis begins. Their findings may also inform the design of new treatments to combat it.
National Institutes of Health

Contact: David Cameron
Harvard Medical School

Public Release: 6-Nov-2014
Journal of Clinical Oncology
Olaparib shows success in tumor response rate for patients with BRCA-related cancers
Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania. The positive response provides new hope for patients with ovarian, breast, pancreatic and prostate cancers whose conditions have not responded to standard therapies. Results of the phase II study are available online in the current issue of the Journal of Clinical Oncology.

Contact: Katie Delach
University of Pennsylvania School of Medicine

Public Release: 6-Nov-2014
Journal of the National Cancer Institute Monographs
Study shows integrative medicine relieves pain and anxiety for cancer inpatients
Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health care providers. The Penny George Institute for Health and Healing researchers found that integrative medicine therapies can substantially decrease pain and anxiety for hospitalized cancer patients. Their findings are published in the current issue of the Journal of the National Cancer Institute Monographs.

Contact: Zachary M Rathner
Oxford University Press USA

Public Release: 6-Nov-2014
Angewandte Chemie
Sorting bloodborne cancer cells to better predict spread of disease
For most cancer patients, primary tumors are often not the most deadly. Instead, it is the metastatic tumors -- tumors that spread from their original location to other parts of the body -- that are the cause of most cancer deaths. Researchers at the University of Toronto have developed a diagnostic tool to investigate traveling cancer cells and improve health outcomes, published in the leading Chemistry journal Angewandte Chemie.

Contact: Jef Ekins
University of Toronto Faculty of Applied Science & Engineering

Public Release: 6-Nov-2014
JAMA Otolaryngology--Head & Neck Surgery
Location of oral cancers differs in smokers, nonsmokers
The location of oral cancers differed in smokers and nonsmokers with nonsmokers having a higher proportion of cancers occur on the edge of the tongue, according to a study published online by JAMA Otolaryngology -- Head & Neck Surgery.

Contact: Christopher F.L. Perry
The JAMA Network Journals

Showing releases 101-125 out of 1268.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 > >>

  Search News Releases